Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Asia-Pacific Advanced HCC
NCT00492752Phase 3Completed
- Sponsor
- Bayer
- Start
- Oct 2005
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Sorafenib with Placebo (2 arms). Primary endpoint: Overall Survival at 23 months. Started Oct 2005; status: completed.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00492752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00492752.